Altered BCR and CD40 signalling are associated with clinical outcome in small lymphocytic lymphoma/chronic lymphocytic leukaemia and marginal zone lymphoma patients.
Altered BCR and CD40 signalling are associated with clinical outcome in small lymphocytic lymphoma/chronic lymphocytic leukaemia and marginal zone lymphoma patients.
复制标题
BCR 和 CD40 信号传导的改变与小淋巴细胞淋巴瘤/慢性淋巴细胞白血病和边缘区淋巴瘤患者的临床结果相关。
DOI：
10.1111/bjh.12073
复制
发表时间：
2012
影响因子：
6.5
通讯作者：
Kolstad,Arne
中科院分区：
文献类型：
--
作者：
Blix,EgilS;Irish,JonathanM;Husebekk,Anne;Delabie,Jan;Tierens,AnneM;Myklebust,JuneH;Kolstad,Arne
小细胞淋巴细胞性淋巴瘤/慢性淋巴细胞性白血病（SLL/CLL）和边缘区淋巴瘤（MZL）是惰性非霍奇金淋巴瘤，其特征在于骨髓、次级淋巴组织和血液中的恶性B细胞。临床过程可以变化，并且与具有突变的IGHV的患者相比，具有未突变的免疫球蛋白重链可变基因（IGHV）的CLL患者具有较短的总生存期（OS）（Dighiero & Hamblin，2008）。此外，B细胞受体（BCR）和CD 40信号传导对于正常和恶性B细胞的存活和增殖是重要的。我们最近在滤泡性淋巴瘤（FL）中发现了一种新的淋巴瘤B细胞亚群，其特征为BCR信号传导受损，并发现该亚群的患病率与初始化疗的应答和OS呈负相关（Irish et al，2010）。本研究调查了SLL/CLL和MZL患者中是否也可以发现类似的淋巴瘤亚群。
Small cell lymphocytic lymphoma/chronic lymphocytic leukaemia (SLL/CLL) and marginal zone lymphoma (MZL) are indolent non-Hodgkin lymphomas, characterized by malignant B cells in bone marrow, secondary lymphoid tissue and blood. The clinical course can vary, and CLL patients with unmutated immunoglobulin heavy chain variable genes (IGHV) have a shorter overall survival (OS) compared to patients with mutated IGHV (Dighiero & Hamblin, 2008). Furthermore, B-cell receptor (BCR) and CD40 signalling are important for the survival and proliferation of normal and malignant B-cells. We recently identified a new lymphoma B cell subset in follicular lymphoma (FL), characterized by impaired BCR signalling, and found that the prevalence of this subset was negatively associated with the response to initial chemotherapy and with OS (Irish et al, 2010). The present study investigated whether a similar lymphoma subset also could be found in SLL/CLL and MZL patients.